SCHEMBL8423829

SCHEMBL8423829

Cc1ccc(S(=O)(=O)OCCCc2ccc3[nH]nc(S)c3c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD10 O75832 1/20 0.37
MAP2K4 P45985 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
CYP24A1 Q07973 2/20 0.33
JAK2 O60674 1/20 0.33
MAPT P10636 3/20 0.32
TP53 P04637 2/20 0.32
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CDK2 P24941 1/20 0.32
LMNA P02545 1/20 0.32
IDO1 P14902 1/20 0.32
STAT3 P40763 1/20 0.32
NPC1 O15118 1/20 0.32
KMT2A Q03164 1/20 0.32
ALDH1A1 P00352 2/20 0.31
NTRK1 P04629 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8233119 0.89 PSMD10 (0.38) PSMD10MAP2K4CA12CA1CA9
SCHEMBL8239638 0.86 PSMD10 (0.36) PSMD10MAP2K4CA12CA1CA9
SCHEMBL3533479 0.83 CYP24A1 (0.36) PSMD10CYP24A1MAPTTP53IDO1
SCHEMBL3527992 0.80 FKBP1A (0.36) PSMD10CYP24A1MAPTTP53IDO1
SCHEMBL3529109 0.78 HTR6 (0.38) CYP24A1
SCHEMBL2567795 0.77 ALDH1A1 (0.47) PSMD10CA12CA1CA9LMNA
SCHEMBL18934371 0.77 ALDH1A1 (0.47) PSMD10CA12CA1CA9LMNA
SCHEMBL3532194 0.76 HTR6 (0.38) CYP24A1
SCHEMBL18934283 0.74 CYP19A1 (0.48) PSMD10CA12CA1CA9CYP24A1
SCHEMBL18926560 0.73 GAA (0.50) PSMD10CA12CA1CA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723329-B2 Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands WYETH LLC (US) 2010-05-25 US disclosed
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders WYETH (US) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037802-A1 such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders HTR6, TPH1, HTR1A PSMD10 2283/4885MAP2K4 3189/4885CA12 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.